Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
AbstractCannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, neuroprotective, antidepressant and anxiolytic. The neuroprotective activity appears linked to its excellent anti-inflammatory and antioxidant properties. The purpose of this paper is to evaluate the use of CBD, in addition to common anti-epileptic drugs, in the severe treatment-resistant epilepsy through an overview of recent literature and clinical trials aimed to study the effects of the CBD treatment in different forms of epilepsy. The results of scientific studies obtained so far the use of CBD in clinical applications could represent hope for patients who are resistant to all conventional anti-epileptic drugs. View Full-Text
Share & Cite This Article
Silvestro, S.; Mammana, S.; Cavalli, E.; Bramanti, P.; Mazzon, E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules 2019, 24, 1459.
Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules. 2019; 24(8):1459.Chicago/Turabian Style
Silvestro, Serena; Mammana, Santa; Cavalli, Eugenio; Bramanti, Placido; Mazzon, Emanuela. 2019. "Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials." Molecules 24, no. 8: 1459.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.